←RETURN TO 2026 IPO RADAR DECK (135 OFFERINGS)COHORT STANDING: #29 of 135
Verified SEC Filing/Calendar Year 2026
NASDAQHealth Care
$AKTS
RANGE-BOUND (-50% to +50%)
Aktis Oncology
Legal Entity: Aktis Oncology, Inc.
OFFER PRICE$20.00
CURRENT PRICE
$26.67
CUMULATIVE RETURN
+33.33%
PRICING DATE: 1/9/2026SEC FILING SNAPSHOT
SECTION 01 // FORENSIC TEARDOWN
The Seagull Executive Verdict
SURVIVAL RATING: WINNER
WHAT THE BUSINESS DOES
Engineers novel targeted alpha-emitter therapies for solid tumors. Operates as a pre-revenue clinical-stage biotechnology company.
THE WALL STREET PITCH
N/A
THE COLD REALITY
N/A
SECTION 02 // CAPITAL ALLOCATION
Capital Formation & Float Scarcity
FLAG: TREASURY GROWTH
Gross Proceeds
$150.0M
Cash extracted from market
Post-Money Value
Undisclosed
Total company valuation
Public Float %
18.5%
Shares available to public
Secondary Share %
0%
Insider cash extraction
CAPITAL USE ANALYSIS
Standard primary capital raise for general working capital.
SECTION 03 // SUPPLY SHOCK AUDITOR
Insider Lock-Up Expiration
VC DUMP RISK: MODERATE
Expiration Calendar Date
2026-07-08
LOCKUP EXPIRED
Supply Shock Multiplier
N/A
Float expansion ratio upon unlock
Lockup Duration
180 Days
Contractual restriction window
SECTION 05 // COHORT BENCHMARK
Sector Peer & Cohort Telemetry
RANK: #29 of 135
2026 Cohort Standing
#29 of 135
Out of 135 total 2026 IPO offerings
Sector Median Return
+21.64%
Health Care sector midpoint
Sector Win Rate
78%
% of peer IPOs trading in profit
PERFORMANCE VS PEERS
Aktis Oncology is currently trading above the Health Care sector median of 21.64%. Across the entire 2026 calendar year cohort, only 78% of Health Care offerings have sustained a positive return above their initial offer price.